Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.

Brandsma AM, Bondza S, Evers M, Koutstaal R, Nederend M, Jansen JHM, Rösner T, Valerius T, Leusen JHW, Ten Broeke T.

Front Immunol. 2019 Apr 11;10:704. doi: 10.3389/fimmu.2019.00704. eCollection 2019.

2.

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.

Logtenberg MEW, Jansen JHM, Raaben M, Toebes M, Franke K, Brandsma AM, Matlung HL, Fauster A, Gomez-Eerland R, Bakker NAM, van der Schot S, Marijt KA, Verdoes M, Haanen JBAG, van den Berg JH, Neefjes J, van den Berg TK, Brummelkamp TR, Leusen JHW, Scheeren FA, Schumacher TN.

Nat Med. 2019 Apr;25(4):612-619. doi: 10.1038/s41591-019-0356-z. Epub 2019 Mar 4.

PMID:
30833751
3.

Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study).

Hoogstad-van Evert J, Bekkers R, Ottevanger N, Schaap N, Hobo W, Jansen JH, Massuger L, Dolstra H.

Medicine (Baltimore). 2019 Feb;98(5):e14290. doi: 10.1097/MD.0000000000014290.

4.

Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes.

Yi G, Wierenga ATJ, Petraglia F, Narang P, Janssen-Megens EM, Mandoli A, Merkel A, Berentsen K, Kim B, Matarese F, Singh AA, Habibi E, Prange KHM, Mulder AB, Jansen JH, Clarke L, Heath S, van der Reijden BA, Flicek P, Yaspo ML, Gut I, Bock C, Schuringa JJ, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA.

Cell Rep. 2019 Jan 22;26(4):1059-1069.e6. doi: 10.1016/j.celrep.2018.12.098.

5.

Molecular mechanisms of bleeding disorderassociated GFI1BQ287* mutation and its affected pathways in megakaryocytes and platelets.

van Oorschot R, Hansen M, Koornneef JM, Marneth AE, Bergevoet SM, van Bergen MGJM, van Alphen FPJ, van der Zwaan C, Martens JHA, Vermeulen M, Jansen PWTC, Baltissen MPA, Gorkom BAPL, Janssen H, Jansen JH, von Lindern M, Meijer AB, van den Akker E, van der Reijden BA.

Haematologica. 2019 Jul;104(7):1460-1472. doi: 10.3324/haematol.2018.194555. Epub 2019 Jan 17.

6.

Inherited missense variants that affect GFI1B function do not necessarily cause bleeding diatheses.

van Oorschot R, Marneth AE, Bergevoet SM, van Bergen MGJM, Peerlinck K, Lentaigne CE, Millar CM, Westbury SK, Favier R, Erber WN, Turro E, Jansen JH, Ouwehand WH, McKinney HL; NIHR BioResource Collaborative Group, Downes K, Freson K, van der Reijden BA.

Haematologica. 2019 Jun;104(6):e260-e264. doi: 10.3324/haematol.2018.207712. Epub 2018 Dec 20. No abstract available.

7.

Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Albano F, Lefrère F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Haematologica. 2019 Jun;104(6):1168-1175. doi: 10.3324/haematol.2018.204826. Epub 2018 Dec 6.

8.

Integrative Proteomic Profiling Reveals PRC2-Dependent Epigenetic Crosstalk Maintains Ground-State Pluripotency.

van Mierlo G, Dirks RAM, De Clerck L, Brinkman AB, Huth M, Kloet SL, Saksouk N, Kroeze LI, Willems S, Farlik M, Bock C, Jansen JH, Deforce D, Vermeulen M, Déjardin J, Dhaenens M, Marks H.

Cell Stem Cell. 2019 Jan 3;24(1):123-137.e8. doi: 10.1016/j.stem.2018.10.017. Epub 2018 Nov 21.

PMID:
30472157
9.

Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients.

Hoogstad-van Evert JS, Maas RJ, van der Meer J, Cany J, van der Steen S, Jansen JH, Miller JS, Bekkers R, Hobo W, Massuger L, Dolstra H.

Oncotarget. 2018 Oct 5;9(78):34810-34820. doi: 10.18632/oncotarget.26199. eCollection 2018 Oct 5.

10.

TCF4 promotes erythroid development.

In 't Hout FEM, van Duren J, Monteferrario D, Brinkhuis E, Mariani N, Westers TM, Chitu D, Nikoloski G, van de Loosdrecht AA, van der Reijden BA, Jansen JH, Huls G.

Exp Hematol. 2019 Jan;69:17-21.e1. doi: 10.1016/j.exphem.2018.10.002. Epub 2018 Oct 10.

PMID:
30315825
11.

Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy.

Mousset CM, Hobo W, Ji Y, Fredrix H, De Giorgi V, Allison RD, Kester MGD, Falkenburg JHF, Schaap NPM, Jansen JH, Gattinoni L, Dolstra H, van der Waart AB.

Oncoimmunology. 2018 Aug 6;7(10):e1488565. doi: 10.1080/2162402X.2018.1488565. eCollection 2018.

12.

Immune Effector Functions of Human IgG2 Antibodies against EGFR.

Rösner T, Kahle S, Montenegro F, Matlung HL, Jansen JHM, Evers M, Beurskens F, Leusen JHW, van den Berg TK, Valerius T.

Mol Cancer Ther. 2019 Jan;18(1):75-88. doi: 10.1158/1535-7163.MCT-18-0341. Epub 2018 Oct 3.

PMID:
30282813
13.

appreci8: a pipeline for precise variant calling integrating 8 tools.

Sandmann S, Karimi M, de Graaf AO, Rohde C, Göllner S, Varghese J, Ernsting J, Walldin G, van der Reijden BA, Müller-Tidow C, Malcovati L, Hellström-Lindberg E, Jansen JH, Dugas M.

Bioinformatics. 2018 Dec 15;34(24):4205-4212. doi: 10.1093/bioinformatics/bty518.

14.

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.

Baron F, Stevens-Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, Halkes CJM, Thomas X, Vrhovac R, Specchia G, Lefrere F Sr, Sica S, Mancini M, Venditti A, Hagemeijer A, Becker H, Jansen JH, Amadori S, de Witte T, Willemze R, Suciu S.

Ann Hematol. 2018 Oct;97(10):1785-1795. doi: 10.1007/s00277-018-3396-4. Epub 2018 Jun 20.

15.

Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia.

Singh AA, Petraglia F, Nebbioso A, Yi G, Conte M, Valente S, Mandoli A, Scisciola L, Lindeboom R, Kerstens H, Janssen-Megens EM, Pourfarzad F, Habibi E, Berentsen K, Kim B, Logie C, Heath S, Wierenga ATJ, Clarke L, Flicek P, Jansen JH, Kuijpers T, Yaspo ML, Valle VD, Bernard O, Gut I, Vellenga E, Stunnenberg HG, Mai A, Altucci L, Martens JHA.

Oncotarget. 2018 May 22;9(39):25647-25660. doi: 10.18632/oncotarget.25429. eCollection 2018 May 22.

16.

GFI1 is required for RUNX1/ETO positive acute myeloid leukemia.

Marneth AE, Botezatu L, Hönes JM, Israël JCL, Schütte J, Vassen L, Lams RF, Bergevoet SM, Groothuis L, Mandoli A, Martens JHA, Huls G, Jansen JH, Dührsen U, Berg T, Möröy T, Wichmann C, Lo MC, Zhang DE, van der Reijden BA, Khandanpour C.

Haematologica. 2018 Sep;103(9):e395-e399. doi: 10.3324/haematol.2017.180844. Epub 2018 Apr 19. No abstract available.

17.

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.

Jacobino SR, Nederend M, Reijneveld JF, Augustijn D, Jansen JHM, Meeldijk J, Reiding KR, Wuhrer M, Coenjaerts FEJ, Hack CE, Bont LJ, Leusen JHW.

MAbs. 2018 Apr;10(3):453-462. doi: 10.1080/19420862.2018.1433974. Epub 2018 Mar 19.

18.

Combined Inhibition of C5 and CD14 Attenuates Systemic Inflammation in a Piglet Model of Meconium Aspiration Syndrome.

Thomas AM, Schjalm C, Nilsson PH, Lindenskov PHH, Rørtveit R, Solberg R, Saugstad OD, Berglund MM, Strömberg P, Lau C, Espevik T, Jansen JH, Castellheim A, Mollnes TE, Barratt-Due A.

Neonatology. 2018;113(4):322-330. doi: 10.1159/000486542. Epub 2018 Feb 27.

19.

New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.

Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, Moerer P, Amini M, Kretschmer A, Ten Broeke T, den Hartog MT, Rijke M, Klein C, Valerius T, Boross P, Leusen JHW.

Br J Haematol. 2018 Mar;180(6):808-820. doi: 10.1111/bjh.15132. Epub 2018 Feb 22.

PMID:
29468712
20.

Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT.

Berger G, Kroeze LI, Koorenhof-Scheele TN, de Graaf AO, Yoshida K, Ueno H, Shiraishi Y, Miyano S, van den Berg E, Schepers H, van der Reijden BA, Ogawa S, Vellenga E, Jansen JH.

Blood. 2018 Apr 19;131(16):1846-1857. doi: 10.1182/blood-2017-09-805879. Epub 2018 Jan 8.

21.

Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation.

Hutten TJA, Norde WJ, Woestenenk R, Wang RC, Maas F, Kester M, Falkenburg JHF, Berglund S, Luznik L, Jansen JH, Schaap N, Dolstra H, Hobo W.

Biol Blood Marrow Transplant. 2018 Apr;24(4):666-677. doi: 10.1016/j.bbmt.2017.11.027. Epub 2017 Dec 26.

22.

Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice.

Cany J, Roeven MWH, Hoogstad-van Evert JS, Hobo W, Maas F, Franco Fernandez R, Blijlevens NMA, van der Velden WJ, Huls G, Jansen JH, Schaap NPM, Dolstra H.

Blood. 2018 Jan 11;131(2):202-214. doi: 10.1182/blood-2017-06-790204. Epub 2017 Nov 14.

23.

Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice.

Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, Bekkers RL, Jansen JH, Massuger LF, Dolstra H.

Oncoimmunology. 2017 May 11;6(8):e1320630. doi: 10.1080/2162402X.2017.1320630. eCollection 2017.

24.

C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.

Marneth AE, Prange KHM, Al Hinai ASA, Bergevoet SM, Tesi N, Janssen-Megens EM, Kim B, Sharifi N, Yaspo ML, Kuster J, Sanders MA, Stoetman ECG, Knijnenburg J, Arentsen-Peters TCJM, Zwaan CM, Stunnenberg HG, van den Heuvel-Eibrink MM, Haferlach T, Fornerod M, Jansen JH, Valk PJM, van der Reijden BA, Martens JHA.

Leukemia. 2018 Mar;32(3):828-836. doi: 10.1038/leu.2017.280. Epub 2017 Sep 5.

PMID:
28871137
25.

Oxidative coupling of Michael acceptors with aryl nucleophiles produced through rhodium-catalyzed C-C bond activation.

Gregerson CE, Trentadue KN, Phipps EJT, Kirsch JK, Reed KM, Dyke GD, Jansen JH, Otteman CB, Stachowski JL, Johnson JB.

Org Biomol Chem. 2017 Jul 19;15(28):5944-5948. doi: 10.1039/c7ob01212h.

PMID:
28675229
26.

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T.

Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27. No abstract available.

PMID:
28449349
27.

Clonal evolution in myelodysplastic syndromes.

da Silva-Coelho P, Kroeze LI, Yoshida K, Koorenhof-Scheele TN, Knops R, van de Locht LT, de Graaf AO, Massop M, Sandmann S, Dugas M, Stevens-Kroef MJ, Cermak J, Shiraishi Y, Chiba K, Tanaka H, Miyano S, de Witte T, Blijlevens NMA, Muus P, Huls G, van der Reijden BA, Ogawa S, Jansen JH.

Nat Commun. 2017 Apr 21;8:15099. doi: 10.1038/ncomms15099.

28.

Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients.

Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, Leenders M, Bohme F, Kok N, Trilsbeek C, Paardekooper J, van der Waart AB, Westerweel PE, Snijders TJF, Cornelissen J, Bos G, Pruijt HFM, de Graaf AO, van der Reijden BA, Jansen JH, van der Meer A, Huls G, Cany J, Preijers F, Blijlevens NMA, Schaap NM.

Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. doi: 10.1158/1078-0432.CCR-16-2981. Epub 2017 Mar 9.

29.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C, Westers TM, Visser-Wisselaar HA, Chitu DA, Cunha SM, Vellenga E, Klein SK, Wijermans P, de Greef GE, Schaafsma MR, Muus P, Ossenkoppele GJ, van de Loosdrecht AA, Jansen JH.

Genes Chromosomes Cancer. 2017 Jul;56(7):524-534. doi: 10.1002/gcc.22455. Epub 2017 Mar 31.

PMID:
28236351
30.

Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data.

Sandmann S, de Graaf AO, Karimi M, van der Reijden BA, Hellström-Lindberg E, Jansen JH, Dugas M.

Sci Rep. 2017 Feb 24;7:43169. doi: 10.1038/srep43169.

31.

GLM-based optimization of NGS data analysis: A case study of Roche 454, Ion Torrent PGM and Illumina NextSeq sequencing data.

Sandmann S, de Graaf AO, van der Reijden BA, Jansen JH, Dugas M.

PLoS One. 2017 Feb 21;12(2):e0171983. doi: 10.1371/journal.pone.0171983. eCollection 2017.

32.

Platelet CD34 expression and α/δ-granule abnormalities in GFI1B- and RUNX1-related familial bleeding disorders.

Marneth AE, van Heerde WL, Hebeda KM, Laros-van Gorkom BA, Barteling W, Willemsen B, de Graaf AO, Simons A, Jansen JH, Preijers F, Jongmans MC, van der Reijden BA.

Blood. 2017 Mar 23;129(12):1733-1736. doi: 10.1182/blood-2016-11-749366. Epub 2017 Jan 17. No abstract available.

33.

Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.

Langemeijer SM, Mariani N, Knops R, Gilissen C, Woestenenk R, de Witte T, Huls G, van der Reijden BA, Jansen JH.

PLoS One. 2016 Nov 30;11(11):e0165582. doi: 10.1371/journal.pone.0165582. eCollection 2016.

34.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, van der Velden VH, Te Marvelde JG, Klein SK, Muus P, Vellenga E, de Greef GE, Legdeur MC, Wijermans PW, Stevens-Kroef MJ, Silva-Coelho PD, Jansen JH, Ossenkoppele GJ, van de Loosdrecht AA; A study on behalf of the HOVON89 study group.

Haematologica. 2017 Feb;102(2):320-326. doi: 10.3324/haematol.2016.147843. Epub 2016 Sep 22.

35.

CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.

Hutten TJ, Thordardottir S, Fredrix H, Janssen L, Woestenenk R, Tel J, Joosten B, Cambi A, Heemskerk MH, Franssen GM, Boerman OC, Bakker LB, Jansen JH, Schaap N, Dolstra H, Hobo W.

J Immunol. 2016 Oct 1;197(7):2715-25. doi: 10.4049/jimmunol.1600011. Epub 2016 Aug 26.

36.

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.

Vikström IB, Slomp A, Carrington EM, Moesbergen LM, Chang C, Kelly GL, Glaser SP, Jansen JH, Leusen JH, Strasser A, Huang DC, Lew AM, Peperzak V, Tarlinton DM.

Cell Death Dis. 2016 Aug 25;7(8):e2345. doi: 10.1038/cddis.2016.237.

37.

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P.

J Immunol. 2016 Aug 1;197(3):807-13. doi: 10.4049/jimmunol.1501351. Epub 2016 Jun 17.

38.

Impairment of DNA Methylation Maintenance Is the Main Cause of Global Demethylation in Naive Embryonic Stem Cells.

von Meyenn F, Iurlaro M, Habibi E, Liu NQ, Salehzadeh-Yazdi A, Santos F, Petrini E, Milagre I, Yu M, Xie Z, Kroeze LI, Nesterova TB, Jansen JH, Xie H, He C, Reik W, Stunnenberg HG.

Mol Cell. 2016 Jun 16;62(6):983. doi: 10.1016/j.molcel.2016.06.005. Epub 2016 Jun 16. No abstract available.

39.

Impairment of DNA Methylation Maintenance Is the Main Cause of Global Demethylation in Naive Embryonic Stem Cells.

von Meyenn F, Iurlaro M, Habibi E, Liu NQ, Salehzadeh-Yazdi A, Santos F, Petrini E, Milagre I, Yu M, Xie Z, Kroeze LI, Nesterova TB, Jansen JH, Xie H, He C, Reik W, Stunnenberg HG.

Mol Cell. 2016 Jun 16;62(6):848-861. doi: 10.1016/j.molcel.2016.04.025. Epub 2016 May 26. Erratum in: Mol Cell. 2016 Jun 16;62(6):983.

40.

Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs.

Chen S, Zambetti NA, Bindels EM, Kenswill K, Mylona AM, Adisty NM, Hoogenboezem RM, Sanders MA, Cremers EM, Westers TM, Jansen JH, van de Loosdrecht AA, Raaijmakers MH.

Leukemia. 2016 Sep;30(9):1938-42. doi: 10.1038/leu.2016.91. Epub 2016 Apr 25. No abstract available.

41.

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.

Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, van der Reijden B, Marneth AE, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrishnan A, Beck D, Pimanda J, Hellström-Lindberg E, Malcovati L, Boultwood J, Pellagatti A, Papaemmanuil E, Le Coutre P, Kaeda J, Opalka B, Möröy T, Dührsen U, Maciejewski J, Khandanpour C.

Exp Hematol. 2016 Jul;44(7):590-595.e1. doi: 10.1016/j.exphem.2016.04.001. Epub 2016 Apr 11.

42.

Is it too early to move to full electronic PROM data collection?: A randomized controlled trial comparing PROM's after hallux valgus captured by e-mail, traditional mail and telephone.

Palmen LN, Schrier JC, Scholten R, Jansen JH, Koëter S.

Foot Ankle Surg. 2016 Mar;22(1):46-9. doi: 10.1016/j.fas.2015.05.001. Epub 2015 May 23.

PMID:
26869500
43.

An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.

Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T.

Cancer Res. 2016 Jan 15;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub 2015 Dec 3.

44.

Allelic Mutations of KITLG, Encoding KIT Ligand, Cause Asymmetric and Unilateral Hearing Loss and Waardenburg Syndrome Type 2.

Zazo Seco C, Serrão de Castro L, van Nierop JW, Morín M, Jhangiani S, Verver EJ, Schraders M, Maiwald N, Wesdorp M, Venselaar H, Spruijt L, Oostrik J, Schoots J; Baylor-Hopkins Center for Mendelian Genomics, van Reeuwijk J, Lelieveld SH, Huygen PL, Insenser M, Admiraal RJ, Pennings RJ, Hoefsloot LH, Arias-Vásquez A, de Ligt J, Yntema HG, Jansen JH, Muzny DM, Huls G, van Rossum MM, Lupski JR, Moreno-Pelayo MA, Kunst HP, Kremer H.

Am J Hum Genet. 2015 Nov 5;97(5):647-60. doi: 10.1016/j.ajhg.2015.09.011. Epub 2015 Oct 29.

45.

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.

Meyer S, Nederend M, Jansen JH, Reiding KR, Jacobino SR, Meeldijk J, Bovenschen N, Wuhrer M, Valerius T, Ubink R, Boross P, Rouwendal G, Leusen JH.

MAbs. 2016;8(1):87-98. doi: 10.1080/19420862.2015.1106658. Epub 2015 Oct 14. Erratum in: MAbs. 2017 Jan;9(1):165.

46.

The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34(+) Hematopoietic Stem and Progenitor Cells.

Roeven MW, Thordardottir S, Kohela A, Maas F, Preijers F, Jansen JH, Blijlevens NM, Cany J, Schaap N, Dolstra H.

Stem Cells Dev. 2015 Dec 15;24(24):2886-98. doi: 10.1089/scd.2014.0597. Epub 2015 Oct 28.

PMID:
26414401
47.

Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.

Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P.

Cancer Immunol Res. 2015 Dec;3(12):1316-24. doi: 10.1158/2326-6066.CIR-15-0099-T. Epub 2015 Sep 25.

48.

Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer.

Cany J, van der Waart AB, Spanholtz J, Tordoir M, Jansen JH, van der Voort R, Schaap NM, Dolstra H.

Oncoimmunology. 2015 Apr 1;4(7):e1017701. eCollection 2015 Jul.

49.

World Small Animal Veterinary Association Renal Pathology Initiative: Classification of Glomerular Diseases in Dogs.

Cianciolo RE, Mohr FC, Aresu L, Brown CA, James C, Jansen JH, Spangler WL, van der Lugt JJ, Kass PH, Brovida C, Cowgill LD, Heiene R, Polzin DJ, Syme H, Vaden SL, van Dongen AM, Lees GE.

Vet Pathol. 2016 Jan;53(1):113-35. doi: 10.1177/0300985815579996. Epub 2015 May 8.

PMID:
25957358
50.

CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder.

Wortmann SB, Ziętkiewicz S, Kousi M, Szklarczyk R, Haack TB, Gersting SW, Muntau AC, Rakovic A, Renkema GH, Rodenburg RJ, Strom TM, Meitinger T, Rubio-Gozalbo ME, Chrusciel E, Distelmaier F, Golzio C, Jansen JH, van Karnebeek C, Lillquist Y, Lücke T, Õunap K, Zordania R, Yaplito-Lee J, van Bokhoven H, Spelbrink JN, Vaz FM, Pras-Raves M, Ploski R, Pronicka E, Klein C, Willemsen MA, de Brouwer AP, Prokisch H, Katsanis N, Wevers RA.

Am J Hum Genet. 2015 Feb 5;96(2):245-57. doi: 10.1016/j.ajhg.2014.12.013. Epub 2015 Jan 15.

Supplemental Content

Loading ...
Support Center